Literature DB >> 1884727

Cyclosporine pharmacokinetics in liver transplant recipients: evaluation of results using both polyclonal radioimmunoassay and liquid chromatographic analysis.

J M Tredger1, J Grevel, N Naoumov, C M Steward, A A Niven, B Whiting, R Williams.   

Abstract

Pharmacokinetic variables were derived from cyclosporine measurements using liquid chromatography (HPLC) and radioimmunoassay with a non-selective polyclonal antibody (PARIA) in 11 orthotopic liver transplant recipients studied in paired oral and intravenous studies both before and after permanent clamping of the biliary T-tube. After oral drug administration, mean areas under blood cyclosporine concentration versus time curves before clamping were around 5.2-fold greater by PARIA than HPLC but 2.9-fold greater after clamping and closer to comparable values after intravenous cyclosporine (2.5 and 2.3-fold, respectively). Cyclosporine clearance was smaller by PARIA than HPLC (mean 7.3 versus 3.3 ml.min-1.kg-1, respectively, before clamping). Both values decreased by 25% after clamping (to 5.5 and 2.4 ml.min-1.kg-1, respectively), although there was no significant change in distribution or elimination half-lives (around 0.5 and 8 h, respectively). The mean bioavailability of oral cyclosporine increased significantly after clamping in 9 patients (from 10.6% to 28.1% by HPLC and from 14.8 to 35.1% by PARIA) but in two patients who developed the vanishing bile duct syndrome values fell to less than 10% and the proportional overestimation of cyclosporine concentrations by PARIA increased. Clamping had no singificant effect on the mean apparent volumes of distribution but values of Vz were approximately twice those of Vss (around 2.6 and 1.31.kg-1 by PARIA and HPLC respectively). Mean half lives after clamping were shorter following oral than intravenous cyclosporine (t 1/2 lambda 2 around 15 h enterally versus 8 h parenterally).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884727     DOI: 10.1007/bf00315232

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  25 in total

1.  Cyclosporin metabolites and neurotoxicity.

Authors:  A K Trull; K K Tan; N B Roberts; J F Tjia; D J Back
Journal:  Lancet       Date:  1989-08-19       Impact factor: 79.321

2.  Pharmacokinetics of oral cyclosporin A (Sandimmun) in healthy subjects.

Authors:  J Grevel; E Nüesch; E Abisch; K Kutz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  The pharmacokinetics of cyclosporine A in uremic patients.

Authors:  A Lindberg; B Odlind; G Tufveson; B Lindström; J Gabrielsson
Journal:  Transplant Proc       Date:  1986-12       Impact factor: 1.066

4.  Cyclosporine monitoring in liver transplant patients.

Authors:  W Andrews; S Iwatsuki; B W Shaw; T E Starzl
Journal:  Transplantation       Date:  1985-03       Impact factor: 4.939

5.  STRIPE: an interactive computer program for the analysis of drug pharmacokinetics.

Authors:  A Johnston; R C Woollard
Journal:  J Pharmacol Methods       Date:  1983-05

6.  Effect of bile on cyclosporin absorption in liver transplant patients.

Authors:  M U Mehta; R Venkataramanan; G J Burckart; R J Ptachcinski; B Delamos; S Stachak; D H Van Thiel; S Iwatsuki; T E Starzl
Journal:  Br J Clin Pharmacol       Date:  1988-05       Impact factor: 4.335

7.  Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants.

Authors:  C W Clardy; T J Schroeder; S A Myre; N K Wadhwa; A J Pesce; M R First; P T McEnery; W F Balistreri; R E Harris; D B Melvin
Journal:  Clin Chem       Date:  1988-10       Impact factor: 8.327

8.  Cyclosporine blood levels--an evaluation of radioimmunoassay with selective monoclonal or polyclonal antibodies and high-performance liquid chromatography in liver transplant recipients.

Authors:  J M Tredger; C M Steward; R Williams
Journal:  Transplantation       Date:  1988-11       Impact factor: 4.939

9.  Trough levels and concentration time curves of cyclosporine in patients undergoing renal transplantation.

Authors:  F J Frey; F F Horber; B M Frey
Journal:  Clin Pharmacol Ther       Date:  1988-01       Impact factor: 6.875

10.  Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA.

Authors:  M R Lucey; J C Kolars; R M Merion; D A Campbell; M Aldrich; P B Watkins
Journal:  Lancet       Date:  1990-01-06       Impact factor: 79.321

View more
  4 in total

Review 1.  Optimisation of immunosuppressive therapy using pharmacokinetic principles.

Authors:  J Grevel
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

2.  Cyclosporin metabolism by human gastrointestinal mucosal microsomes.

Authors:  I R Webber; W H Peters; D J Back
Journal:  Br J Clin Pharmacol       Date:  1992-06       Impact factor: 4.335

Review 3.  A review of assay methods for cyclosporin. Clinical implications.

Authors:  K T Kivistö
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

Review 4.  Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation.

Authors:  Zahra Tolou-Ghamari
Journal:  J Nephropathol       Date:  2012-04-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.